COMPANY

Lifordi Immunotherapeutics

HQ: Boston, MA source · lifordi.com ↗ · New England

Lifordi Immunotherapeutics's website says: "Lifordi is a clinical-stage biotech company developing ADCs that target immune cells to treat autoimmune and inflammatory disorders with precision." From company website Source · Oct 13, 2026

Keywords: adcs Rheumatoid Arthritis inflammatory diseases LFD-200

Location: Boston, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)1NIH grants

Timeline

Nov 18, 2025 Raise Private placement: amount not published, announced Nov 18, 2025. Source: company's own press page. source ↗
Oct 6, 2025 Trial start Phase 1: Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis source ↗

Upcoming milestones

Jul 16, 2027 (ESTIMATED) · Phase 1 · Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis · NCT07207954

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: amount not published. Last 2 years.

Nov 18, 2025 Private placement: amount not published, announced Nov 18, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07207954	Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis	Phase 1	Recruiting	Oct 6, 2025	Jul 16, 2027 (estimated)

NIH awards 1

Annual award amounts. Total $994K.

Jun 25, 2024 NIH award 7R44AI165119-04 FY2023: $993,646 awarded for that fiscal year; activity R44 (SBIR); PI ROTHSTEIN, JAY L; recipient as written: LIFORDI IMMUNOTHERAPEUTICS, INC., BOSTON, MA. Immune cell targeting of corticos source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of ARCH Venture Partners (captured Oct 12, 2026). portfolio page ↗
InvestorListed in the portfolio of Atlas Venture (captured Oct 12, 2026). portfolio page ↗